ActoGenix and the University of Leuven announce a promising breakthrough in the treatment of Type 1 diabetes

Prof. Chantal Mathieu and her team at the University Hospital of Leuven have realized a major breakthrough in the treatment of Type 1 diabetes with an ActoBioticTM , developed by ActoGeniX. Prof. Mathieu has published the results of the study in a mouse model of Type 1 diabetes in the authoritative Journal of Clinical Investigation. The ActoBioticTM can stably reinstate normal glucose levels in Type 1 diabetic mice. ActoBiotics™ represent a novel class of orally administered and locally acting biopharmaceuticals.

The study demonstrates that oral intake of ActoBioticsTM provide a novel and safe strategy to control Type 1 diabetes. This innovative and effective strategy was without side effects and can now be further developed for human application. Type 1 diabetes is the most common metabolic disease in young people. About two million people (around 0.5 % of the population) in Europe and several million people world-wide suffer from this disease.

Further information

University of Leuven
Dr. Chantal Mathieu – Tel. +32 (0) 16 34 60 23 – chantal.mathieu@uzleuven.be

ActoGeniX
Dr. Pieter Rottiers – Tel. +32 (0) 9 261 06 00 – pieter.rottiers@actogenix.com

Press contact

KU Leuven, press relations
Sigrid Somers – Tel. +32 (0) 475 87 40 08 – persdienst@kuleuven.be

Across
Luc Osselaer – Tel. +32 (0) 476 45 15 01 – luc.osselaer@a-cross.com

 

Source: Gimv Venture Capital Portfolio Newsletter